Status:
WITHDRAWN
Glycemic Impact on Glioblastoma Outcomes
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Sinai Health System
Conditions:
Glioblastoma Multiforme
Hyperglycemia
Eligibility:
All Genders
18+ years
Brief Summary
This pilot study aims to evaluate the feasibility of close glucose monitoring and management of patients (targeting fasting and pre-meal glucose of 4-7 mmol/L) using state-of-the-art flash glucose mon...
Detailed Description
The purpose of this pilot study is to determine the feasibility of using close monitoring and management of glucose levels in patients undergoing radiation and chemotherapy for glioblastoma. The gluc...
Eligibility Criteria
Inclusion
- Adult patients (\> 18 years old) with a new histologically-confirmed diagnosis of glioblastoma who are planned to receive a 6-week course of concurrent radiation and temozolomide
- Has evidence of random glucose of at least 7.8 mmol/L or fasting blood glucose of at least 6.1 mmol/L (meeting criteria for oral diabetic medications)
- Able to provide informed consent
- Able to understand and follow instructions regarding self-administered capillary glucose measurements
Exclusion
- Contraindication to MRI with gadolinium
- Taking anti-hyperglycemic medications at the time of study eligibility screen
- Unable to participate in neurocognitive evaluation in English
Key Trial Info
Start Date :
December 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 24 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03235934
Start Date
December 1 2018
End Date
January 24 2020
Last Update
October 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9